Current approaches to novel therapeutics in pancreatic cancer

Corina E. Akerele, Irina Rybalova, Howard L. Kaufman, Sridhar Mani

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Pancreatic cancer is one of the most refractory neoplasms to medical treatment. Until now there has been only modest improvement in the treatment of this disease. Standards of care for combined-modality treatment of resectable as well as locally advanced, unresectable disease have not been uniformly accepted to date because of an equivocal or conflicting data. The inception of gemcitabine introduced the new era in the management of metastatic pancreatic cancer, however, new therapeutic approaches still need to be defined. The article discusses the current knowledge of the biology of this lethal disease, its impact on treatment options, and explores novel therapeutic modalities that are likely to improve outcomes and survival for patients in the future.

Original languageEnglish (US)
Pages (from-to)113-129
Number of pages17
JournalInvestigational New Drugs
Volume21
Issue number1
DOIs
Publication statusPublished - Feb 1 2003

    Fingerprint

Keywords

  • New therapeutic modalities
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this